These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1122 related articles for article (PubMed ID: 27884722)
21. Sequential docetaxel as adjuvant chemotherapy for node-positive or/and T3 or T4 breast cancer: clinical outcome (Mansoura University). Sakr H; Hamed RH; Anter AH; Yossef T Med Oncol; 2013 Mar; 30(1):457. PubMed ID: 23322524 [TBL] [Abstract][Full Text] [Related]
22. Randomized clinical trial of adjuvant fluorouracil, epirubicin, and cyclophosphamide chemotherapy for patients with fast-proliferating, node-negative breast cancer. Paradiso A; Schittulli F; Cellamare G; Mangia A; Marzullo F; Lorusso V; De Lena M J Clin Oncol; 2001 Oct; 19(19):3929-37. PubMed ID: 11579113 [TBL] [Abstract][Full Text] [Related]
23. Effectiveness of an Adjuvant Chemotherapy Regimen for Early-Stage Breast Cancer: A Systematic Review and Network Meta-analysis. Fujii T; Le Du F; Xiao L; Kogawa T; Barcenas CH; Alvarez RH; Valero V; Shen Y; Ueno NT JAMA Oncol; 2015 Dec; 1(9):1311-8. PubMed ID: 26402167 [TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of taxane plus anthracycline with or without cyclophosphamide in Chinese node-positive breast cancer patients: an open-label, randomized controlled trial. Lin Y; Wang C; Huang X; Zhou X; Zhou Y; Mao F; Guan J; Song Y; Zhong Y; Xu Y; Sun Q Breast Cancer Res Treat; 2019 Jun; 175(3):659-666. PubMed ID: 30937656 [TBL] [Abstract][Full Text] [Related]
25. FEC versus sequential docetaxel followed by epirubicin/cyclophosphamide as adjuvant chemotherapy in women with axillary node-positive early breast cancer: a randomized study of the Hellenic Oncology Research Group (HORG). Polyzos A; Malamos N; Boukovinas I; Adamou A; Ziras N; Kalbakis K; Kakolyris S; Syrigos K; Papakotoulas P; Kouroussis C; Karvounis N; Vamvakas L; Christophyllakis C; Athanasiadis A; Varthalitis I; Georgoulias V; Mavroudis D Breast Cancer Res Treat; 2010 Jan; 119(1):95-104. PubMed ID: 19636702 [TBL] [Abstract][Full Text] [Related]
26. Persistent pain, sensory disturbances and functional impairment after adjuvant chemotherapy for breast cancer: cyclophosphamide, epirubicin and fluorouracil compared with docetaxel + epirubicin and cyclophosphamide. Andersen KG; Jensen MB; Kehlet H; Gärtner R; Eckhoff L; Kroman N Acta Oncol; 2012 Nov; 51(8):1036-44. PubMed ID: 22676048 [TBL] [Abstract][Full Text] [Related]
27. Long term effects of extended adjuvant endocrine therapy on quality of life in breast cancer patients. Kool M; Fontein DB; Meershoek-Klein Kranenbarg E; Nortier JW; Rutgers EJ; Marang-van de Mheen PJ; van de Velde CJ Breast; 2015 Jun; 24(3):224-9. PubMed ID: 25704982 [TBL] [Abstract][Full Text] [Related]
28. Impact of Adjuvant Anthracycline-Based and Taxane-Based Chemotherapy on Plasma VEGF Levels and Cognitive Function in Breast Cancer Patients: A Longitudinal Study. Ng T; Phey XY; Yeo HL; Shwe M; Gan YX; Ng R; Ho HK; Chan A Clin Breast Cancer; 2018 Oct; 18(5):e927-e937. PubMed ID: 29705024 [TBL] [Abstract][Full Text] [Related]
29. [Autologous cytokine-induced killer cells therapy on the quality of life of patients with breast cancer after adjuvant chemotherapy: a prospective study]. Liang XF; Ma DC; Ding ZY; Liu ZZ; Guo F; Liu L; Yu HY; Han YL; Xie XD Zhonghua Zhong Liu Za Zhi; 2013 Oct; 35(10):764-8. PubMed ID: 24378099 [TBL] [Abstract][Full Text] [Related]
30. Gemcitabine, epirubicin, and paclitaxel versus fluorouracil, epirubicin, and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: a Central European Cooperative Oncology Group International, multicenter, prospective, randomized phase III trial. Zielinski C; Beslija S; Mrsic-Krmpotic Z; Welnicka-Jaskiewicz M; Wiltschke C; Kahan Z; Grgic M; Tzekova V; Inbar M; Cervek J; Chernozemsky I; Szanto J; Spanik S; Wagnerova M; Ghilezan N; Pawlega J; Vrbanec D; Khamtsov D; Soldatenkova V; Brodowicz T J Clin Oncol; 2005 Mar; 23(7):1401-8. PubMed ID: 15735116 [TBL] [Abstract][Full Text] [Related]
31. Health-related quality of life in early breast cancer. Groenvold M Dan Med Bull; 2010 Sep; 57(9):B4184. PubMed ID: 20816024 [TBL] [Abstract][Full Text] [Related]
32. [Nausea, vomiting and quality of life in women with breast cancer receiving chemotherapy]. Gozzo Tde O; Moysés AM; da Silva PR; de Almeida AM Rev Gaucha Enferm; 2013 Sep; 34(3):110-6. PubMed ID: 24344592 [TBL] [Abstract][Full Text] [Related]
33. UCBG 2-04: Long-term results of the PACS 04 trial evaluating adjuvant epirubicin plus docetaxel in node-positive breast cancer and trastuzumab in the human epidermal growth factor receptor 2-positive subgroup. D'Hondt V; Canon JL; Roca L; Levy C; Pierga JY; Le Du F; Campone M; Desmoulins I; Goncalves A; Debled M; Rios M; Ferrero JM; Serin D; Hardy-Bessard AC; Piot G; Brain E; Dohollou N; Orfeuvre H; Lemonnier J; Roché H; Delaloge S; Dalenc F Eur J Cancer; 2019 Nov; 122():91-100. PubMed ID: 31634648 [TBL] [Abstract][Full Text] [Related]
34. Epirubicin Plus Cyclophosphamide Followed by Docetaxel Versus Epirubicin Plus Docetaxel Followed by Capecitabine As Adjuvant Therapy for Node-Positive Early Breast Cancer: Results From the GEICAM/2003-10 Study. Martín M; Ruiz Simón A; Ruiz Borrego M; Ribelles N; Rodríguez-Lescure Á; Muñoz-Mateu M; González S; Margelí Vila M; Barnadas A; Ramos M; Del Barco Berron S; Jara C; Calvo L; Martínez-Jáñez N; Mendiola Fernández C; Rodríguez CA; Martínez de Dueñas E; Andrés R; Plazaola A; de la Haba-Rodríguez J; López-Vega JM; Adrover E; Ballesteros AI; Santaballa A; Sánchez-Rovira P; Baena-Cañada JM; Casas M; del Carmen Cámara M; Carrasco EM; Lluch A J Clin Oncol; 2015 Nov; 33(32):3788-95. PubMed ID: 26416999 [TBL] [Abstract][Full Text] [Related]
35. Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression. Nitz U; Gluz O; Huober J; Kreipe HH; Kates RE; Hartmann A; Erber R; Moustafa Z; Scholz M; Lisboa B; Mohrmann S; Möbus V; Augustin D; Hoffmann G; Weiss E; Böhmer S; Kreienberg R; Du Bois A; Sattler D; Thomssen C; Kiechle M; Jänicke F; Wallwiener D; Harbeck N; Kuhn W Ann Oncol; 2014 Aug; 25(8):1551-7. PubMed ID: 24827128 [TBL] [Abstract][Full Text] [Related]
36. Association Between Use of a Scalp Cooling Device and Alopecia After Chemotherapy for Breast Cancer. Rugo HS; Klein P; Melin SA; Hurvitz SA; Melisko ME; Moore A; Park G; Mitchel J; Bågeman E; D'Agostino RB; Ver Hoeve ES; Esserman L; Cigler T JAMA; 2017 Feb; 317(6):606-614. PubMed ID: 28196257 [TBL] [Abstract][Full Text] [Related]
37. Prognostic Impact of Weight Change During Adjuvant Chemotherapy in Patients With High-Risk Early Breast Cancer: Results From the ADEBAR Study. Mutschler NS; Scholz C; Friedl TWP; Zwingers T; Fasching PA; Beckmann MW; Fehm T; Mohrmann S; Salmen J; Ziegler C; Jäger B; Widschwendter P; de Gregorio N; Schochter F; Mahner S; Harbeck N; Weissenbacher T; Jückstock J; Janni W; Rack B Clin Breast Cancer; 2018 Apr; 18(2):175-183. PubMed ID: 29598955 [TBL] [Abstract][Full Text] [Related]
38. Dose-dense paclitaxel versus docetaxel following FEC as adjuvant chemotherapy in axillary node-positive early breast cancer: a multicenter randomized study of the Hellenic Oncology Research Group (HORG). Saloustros E; Malamos N; Boukovinas I; Kakolyris S; Kouroussis C; Athanasiadis A; Ziras N; Kentepozidis N; Makrantonakis P; Polyzos A; Christophyllakis C; Georgoulias V; Mavroudis D Breast Cancer Res Treat; 2014 Dec; 148(3):591-7. PubMed ID: 25399229 [TBL] [Abstract][Full Text] [Related]
39. Safety and Tolerability of Anthracycline-Containing Adjuvant Chemotherapy in Elderly High-Risk Breast Cancer Patients. Karavasilis V; Papadimitriou C; Gogas H; Kouvatseas G; Pentheroudakis G; Koutras A; Christodoulou C; Bafaloukos D; Samantas E; Pisanidis N; Papakostas P; Aravantinos G; Karanikiotis C; Kosmidis P; Pectasides D; Dimopoulos MA; Fountzilas G Clin Breast Cancer; 2016 Aug; 16(4):291-298.e3. PubMed ID: 26791750 [TBL] [Abstract][Full Text] [Related]
40. High-dose sequential chemotherapy with recombinant granulocyte colony-stimulating factor and repeated stem-cell support for inflammatory breast cancer patients: does impact on quality of life jeopardize feasibility and acceptability of treatment? Macquart-Moulin G; Viens P; Palangié T; Bouscary ML; Delozier T; Roché H; Janvier M; Fabbro M; Moatti JP J Clin Oncol; 2000 Feb; 18(4):754-64. PubMed ID: 10673516 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]